Omeros Corp.

Omeros Corp. is a clinical-stage biopharmaceutical company discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Lead drug product Omidria (OMS302) for lens replacement surgery is under review for marketing approval by both FDA and the European Medicines Agency, with U.S. commercial launch planned for H2/14. Omeros' five other clinical programs are focused on schizophrenia; Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros' proprietary G protein-coupled receptor (GPCR) platform is making available many new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Expert Comments:

Jason Kolbert, Maxim Group (5/12/15)
"Omeros Corp. reported Omidria sales of $0.2M for Q1/15 after a controlled launch that began in February 2015. This number is in line with our lowered expectations after discussions with the company and in consideration of a test launch. . .we are more excited long term for the Omeros pipeline products. . .in February, the company began a controlled launch to test its marketing and distribution systems, gather feedback from surgeons after using the product, and determine reimbursement timing. . .the company also reported progress toward European approval, with an opinion from Europe's Committee for Medicinal Products for Human Use expected during Q2/15."

Ram Selvaraju, MLV & Co (5/11/15)
"Sales of Omeros Corp.'s lead marketed agent, Omidria, were $238K in Q1/15; we note that this performance was associated with the controlled launch of the drug and that the full rollout is currently underway. The firm is likely to receive formal approval for Omidria in Europe within the coming weeks, in our view; that could catalyze an ex-U.S. partnership on the drug."

Prescient Investment Analysis, Seeking Alpha (4/16/15)
"There are many reasons to believe that Omeros Corp.'s Ophthalmic product Omidria can be successful in domestic markets. Safety, ease of access, reduced stress upon surgeons, and reimbursement for use combine to make questions involving when it will be widely used more pressing than uncertainties pertaining to if it is going to happen. . .under conservative assumptions, Omidria can potentially generate $600M domestic sales revenue five years from now. . .worth over $200M to the corporation. Omidria appears to be a lucrative project that will finance the development of Omeros's pipeline!"

Jason Kolbert, Maxim Group (4/14/15)
"Omeros Corp. announced this morning that the presiding European regulatory authority has approved the company's investigational product OMS-721 for compassionate use. . .[in] the treatment of thrombotic microangiopathies. . .the two patients in the compassionate use study suffer from atypical hemolytic uremic syndrome and were enrolled in the first cohort of the Phase 2 clinical trial. Based on improvements across markers of disease activity in that cohort, the investigator requested that the company continue to provide OMS-721 so that the patients could extend their treatments."

"Omeros Corp. is an exciting company, and the CEO, Dr. Gregory Demopulos, is brilliant. The company is now in the early stages of launching Omidria (phenylephrine + ketorolac), for maintaining pupil dilation during surgery and reducing post-operative pain. While we are excited for the prospects for this drug, we view this as a means for the company to fund one of the most exciting biotechnology pipelines in the industry. The pipeline includes a PDE10 drug targeting schizophrenia and Huntington's disease, an antibody that targets the MASP-2 protein and may show efficacy in complement activation pathway disorders such as atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP) and neovascular age-related macular degeneration (AMD)." read more >

Jason Kolbert, Maxim Group (4/2/15)
"Omeros Corp. announced the nationwide commercial availability of Omidria for intraocular administration during cataract surgery and other intraocular lens replacement procedures to prevent intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. . .the Centers for Medicare & Medicaid Services has set the reimbursement rate for Omidria under Medicare Part B at the product's wholesale acquisition cost of $465 plus 6% per single-use vial. This price is above our expectations and should represent upside to our forecast."

More Expert Comments

Experts Commenting on This Company

Steve Brozak – WBB Securities
Mick Cooper – Edison Investment Research
Jason Kolbert – Maxim Group
John McCamant, Editor – Medical Technology Stock Letter
Liana Moussatos, Analyst – Wedbush
Ram Selvaraju – MLV & Co
George Zavoico, Senior Equity Analyst – JonesTrading International Services LLC

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.